Actively Recruiting
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
Led by Indiana University · Updated on 2026-01-15
10
Participants Needed
1
Research Sites
55 weeks
Total Duration
On this page
Sponsors
I
Indiana University
Lead Sponsor
P
ProMedTek, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research project is designed to see if treatment with the Replexa+ shortwave diathermy device daily for 3 months will improve blood flow in the lower legs and feet of patients diagnosed with peripheral artery disease and peripheral neuropathy.
CONDITIONS
Official Title
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of peripheral artery disease (PAD).
- Claudication of the index limb (Rutherford Category 2 or 3) with documented pain when walking.
- Ankle brachial index (ABI) greater than or equal to 0.6 mmHg measured within 6 months prior to screening or resting toe brachial index (TBI) greater than or equal to 0.4 measured within 6 months prior to screening.
- If ankle and toe systolic pressures are unavailable due to calcification or toe amputation, angiographic data is acceptable to determine blockages or reduced perfusion.
- Diagnosis of peripheral neuropathy confirmed by medical record review.
- Able to give consent.
- Age 18 years or older.
You will not qualify if you...
- Impaired skin integrity in the treatment location(s).
- Current wounds or ulcerations.
- Diagnosis of active bleeding tendencies, hemorrhage, or thrombosis.
- 2+ pitting edema in either lower extremity.
- Active infection defined as elevated white blood cell count >11,500/µL or fever >101.5°F or currently taking antibiotics for infection.
- Presence of implanted electronic or metal devices such as pacemaker, bladder stimulator, spinal cord stimulator, electrodes for myoelectric prosthesis, IUD, surgical staples, or metallic leads in the treatment area.
- Pregnancy.
- Renal disease with creatinine >2.5 mg/dl or eGFR <30 mL/min, or receiving chronic hemodialysis.
- History of skeletal tuberculosis.
- Rapidly deteriorating limb condition that may require major amputation within 30 days.
- Conditions impairing cognitive function.
- Severe additional diseases or conditions that the investigator considers exclusion criteria.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Richard L. Roudebush Veterans Affairs Medical Center
Indianapolis, Indiana, United States, 46202
Actively Recruiting
Research Team
K
Kristen Evans, RN, CCRC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here